Aleafia Health is announcing its global expansion with the closing of its previously announced investment in CannaPacific, a federally licensed Australian medical cannabis company located in New South Wales, Australia.
CannaPacific is licensed by the Office of Drug Control (ODC) of Australia to cultivate medical cannabis (License MC020/18) and to research medical cannabis (License RL 012/18). CannaPacific has also applied for a manufacturer’s license which has been reviewed by the ODC.
108,000 sq. ft. greenhouse
CannaPacific recently won the bid to acquire a horticultural property with extensive greenhouses and infrastructure. The property is situated in the iconic Byron Bay region of New South Wales. Upon closing of the property acquisition, CannaPacific will begin retrofitting of the facility, which boasts 108,000 sq. ft. (10,000 sq. m.) of greenhouse cultivation area. The acquisition significantly accelerates CannaPacific’s early mover advantage in Australia’s budding medical cannabis sector. The property also has local government approval for a subsequent 110,000 sq. ft. expansion of the facility. CannaPacific is currently preparing an amendment to their existing licences to conduct cultivation and research at this property.
For more information:
Aleafia Health
8810 Jane Street, 2nd Floor
Concord, ON
L4K 2M9
Office: 416-860-5665
Fax: 416-860-5626
Toll-free: 1 (844) 258-0583
aleafiainc.com